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d~fferent marl'fade Of indu¢IKm, AF i ~  by Bu and A show ~lim~lar mod~r- 
ate conslMency of shod.tem~ actNMton o~mctlon whah differs mafkeofy from 
VF, 3) Geometric or n~¢han~st~ ffemraes may b~ respon~l~o for these 
of~mwal~r~. 
~ l ' h e  ~ of  BI~41aIt~W Cell Output  to Pf~l lat  
I .N lon  Formation and PY~vent R IpM Imp~km¢o 
R IR  
RR Shamlzl. O.S, H~. F.I. Mlratm, M. Bo~no~ J, Taylor, L Aakof. ~ y  
at Ar(~Tona. lbcson. AZ. US4 
Wh~ I1~ o!oatmde~ ol lwo m~als am i~ced m co.act ~th tm~., an ~lec- 
t~  Curr~t m prnducecl lt~l m diW¢lly pmport~tal to me lemperal~m ~l ih~ 
o~1~ m m o f ~  o ~ ~ .  B~-~ bedew ce~ cumin1 roaches 
a maximum level to,owed ~ a ¢ l~e t~om the steep n~e in impeda,¢= 
is seen~ .. ' !~  eR~mmeflt was ¢~f~' r~ to ¢~erve IP.e lemPeralum at whah 
I t~ occ'w~ and to eva~uate whemer ma~ c~t ot~Put pmdCm l~mn 
ton~a~m. 
AAk~to¢ls: A ~.F EPT cal~tm w~t a ~ motm/e~ on the l~p o! a 
4 mm distal ete¢'Wode was u~JL Fre=h bovine ~ myoca~um was 
~ a lemperam~ -~,'~ed ~ web o ~ g  b~ne I~od. In 
the flint ~:~ce~, rad~ole~lueeay (RF) eeer~ was ~ at a coneumt kwel 
of 3or. RF ~bon ~ ~led  whe~ ce~ output decreased below 
20% ol ~ bi~-battefy level. In the e~o~o,-,6 protocol, RF energy was rinsed 
m a Slep w~e ~ ~11~t t!,Be w~ a steep nse m impedanca. Lesmns 
were measured ~ m,~l were ~mmed ~ mWo t~e l~razol i~, A tofal 
Of 12 e ~  al~Ik~Itiorts were m~ti~. 
Resu~: 1"he temperetum at mmamum b~0~Im,eW cen oulput was 70_8 
± 3.8~'C ~lth born l~otocols and them was a linear con~ation between the 
cell ~0~tage and ~ mem~lor temperature (~ = 0-96 -+ 0.02). Ma~irm.,m cell 
outpuUoltowed by a 20% drop. resulted m lesion fom~atmn at all lhe ablatmn 
s~les with mean les~on ~ of 6.5 ,~ 5.4 ,, 5.4 mm (length ,, molh ,, 
G~13th) and ~rere was no dlfferenoB in MS~I s~e Jn U1ese two pretoo01s. 
~ :  Mmomum bio-bage~ cell output pmdicts lesmn ~rma~.  
Maxmaum cell voflage may be used to ~ a feeat~ack loop to decrease 
the RF energy level to prevent issue chamng and ra~ m,t~nce nse. 
[ 1072-171 I The Appmpdate Isthmus Size for Maze 
Procedure 
T.-J. Wu, M. Yashima. Y.-H. Kim. C.A. Atl~ll, MC Fishbein, 
HS  Karagueu~an. P.-S Chen Cedars-Sinai Med Ctr and UCL~ ~ ot 
Med. Los Angeles, CA. USA 
Backgtout~: The gcal of maze prOcedure is to prevent atnal libnlla~on but 
allow sinus impulses to propagate via an isthmus, wh:.ch connects ~qable atnal 
tissues. The size and structure of [sthmus asseoated w~th th,s destrabte ffect 
remain unclear. 
Methods: Endocard~al isthmuses ot decreasing sizes |2. 1 and 0.5 cm) 
were created in five isolated and perfused canine nght atha (3.8 by 32 cm) 
in the presence Of 1-5 uM of ACh The cuts spared the -¢p~rd~um. "['he 
tissues were paced at increasing rates from either site of the isthmus, and 
the resultant actwation Pagem was mapped from the opmardium using 477 
bipolar electrodes (1,6 mm apart. 
Resu/ts: With istt,muses 2 & ~ cm wide, regular pacing at Ct of 150 ms 
from either st(~e of the cut allowed impulses to conduct to the other side 
across the isthmus. Rapid pacing could induce either multiple WFs wdh 
"fibrillation'-type activity, or single stationary RWF (CL: 106 ± 17 ms) with 
"flutter'-type activity. Both types of WFs were able to propagate across the 
isthmus. With an isthmus of 0.5 cm. only single stationary RWF with a longer 
CL (138 ± 23 ms, p < 0.05) could be induced. This RWF consistently failed to 
propagate across the isthmus, while paced WFs could conduct in 1:1 fashion 
down to CL of 140--160 ms (n = 3) with pectinate muscle (PM) in the isthmus. 
or to CL of 250-300 ms (n = 2) without PM in the isthmus. 
Conclusmns: An endocardial isthmus of 0.5 cm prevents the propagation 
of RWFs and the generation of multiple WFs, while allowing paced WFs to 
conduct. The presence of PM in the isthmus increases the safety factor for 
impulse propagation at regular pacing. 
11072-172 I Dispersion of Atrial Refractoriness and Atrial 
I ! Fibrillation Vulnerability: Relationship to 
Anatomic Site and Basic Cycle Length 
F.X. Roithinger, P.R. Steiner, M.R. Karch. D. Scholtz, M. Chin. C. Stillson. 
A. SippensGroenewegen, M.D. Lesh. University of CaMornia San Francisco. 
San Francisco, CA, USA 
Background: An animal model of nght atrial pacing in order to study atrial 
t~brlllat~'~ (AF) is widely used. but the m~cl~amsm~ of ~ aevelopmem of 
a rtwemble ainal myopathy am IPOO~ly uederstoo~ We hypothes~e that a 
d*ffemnt degm~ of o~pers~n Of refr~Pc1onre~s and vul~erat~hly for t ~  
Of no~suslaine~ AF between tml~¢u!ated (T} and smooth ngh~ atrium (SR&) 
may conthbuto lo ,~t~atmn and m~inter~mce of AF 
Me~PIO<~: In 12 Ilealtlly ¢ ~  mong~ do~ weq~ ~.4  ¢ 1 
k(~ Pm0r~ ~la f ie~ w~ p e ~  hem ~ t r~ O~ me TRA aee ~ 
on 1~.~ SRA, A pmmat, m b¢~l w~ m t ~  L~m~P4! m ~ ~ .  m 
10 ~ Steps tml~t ~ m ~ e l  IERP) w~ ~ ~ a 
mA. AF vtdner~ility ~mt~n (VUL) w~ d~dte~ ~, th~ ietew=d betwe~ fire 
~z :  Them w~m ~ ~,~-~',,~1 ~ ~ pa~ng ~ be. 
tv,~ee~ TRA a~l SPA (0.~ :~ 0,25 V~ 0,33 ~: 0.24 ~) .  
(ERP (m) 97z 17 t00~25 ~t  t4 ~a~ 
~'D IEflP (m~s) 17 ~. 5" 25 ± 6" 14 ¢ 5' ~ ~: 7' 
AF VI~L (ms) ~ t ;~'§ 42 "~ 29' ;~3 ~- 21"r~ 35 t ;~5" 
SD = ~ o n ;  ', t = p ~ 005; " = p -~ 0.01 
Cotc/t~o~: The e~mmn of retrectonnees i w~er, and the ~ 1 ~  
for ir1£hCtlOrl 0t AF is mcreal~ on the sn~.  as conlt~lred to th~ trabGcL~ 
lated R~ ~ n y  ®nag Cow paang trees. ~ ~ may co~m1~te 
1o initiatmn and maintenance d AFm the canine model of rap~l RA pacing. 
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I, o73-::'31 m,g 
Response in IJhe MUSTT Trial 
M.R Gold, G.E Haffey, L_A. Dmaflo. M.H. Leltmatm, R.L Page, K.L Lee, 
A.E. Buxlon. U~m/fy  of Mar)dand, Ba/timom., MD. USA 
Back~:~nd. Patients (pts) ~ drug tetraclop/ventricutar ~fdm (VT) 
are at high risk for sustained arthylhrnzas and death. However, the clmmal 
charactenst¢~ which pmdct the ~ to anPa~,c  de.~e are 
well descnbed. 
Methods: We analysed pts in the MUSTT study rano~mtzed to antiarrhyth- 
mm therapy. All pls had coronary disease, an electron fraction (EF) -~0,40, 
unsuStained VT and reducible sustained VT or f~bnllatwno (VF) 
Results: There were t27 drug responders (38%} ol the 330 pCs tested, Of 
the responders. 88 (6EP~,) were suppressed ~ the first randorr~zed rug 
rested. The rP'Juct~on of VF at baseline was associated wdh a higher response 
rate than the mductson o! mortomoq~ VT (6"P/,, v~ 34%, p = 0.001), and 
the med~n cycle length of monomoq~c VT was shorter in res~,~rs  man 
non.responders (240 v.~ 2-30 ms, p = 0,025), ~ r .  din~al o'larac~l'~t~ 
such as age, gender, El:. I~eart a~re (CHF). previous revasculanzaflon or 
exfent of coronary d~sease ~ not predat <~Kj re~:~-,se (p's > 0,05). 
R ~  Nent'e,monde~ 
Age lye) 68 67 
Gender (%male) 9,4 8¢3 
EF O30 0.30 
CHF J,%) 67 80 
Conclusmn: The ino'uoble rhythm, but not clinical charactertst=cs, orrelate 
with antiarrhylmic drug response in this population 
1073-1741 Elactrophysiology Study Characleristlcs: 
Correlation With Cardiac Death and Defibrillator 
Shocks in the Multlcentar Automated 
Defibril lator Implantation Trial 
D.D Narufa. J.S. Steinberg. F.A. Ehlert. M.E Vloka. W. Zareba. For the 
MADIT investigators: St, Luke's-Roosevelt Hospital & Unto. at Rochester 
Medical Center. New York. USA 
Pts with CAD. poor LV function and unsustained VT are at a higher risk of 
death when sustained ventricular arrhylhm,a is inducible and non-suppress- 
ible at electmphysiology study (EPS). The assooation between •e method 
of induction, the nature of the induced VTNF & the outcome has not been 
studied. We used the MADIT database to compare survwors (n = 142) with 
cardiac deaths (n = 38), and pts with defibrillators who never received shocks 
(n = 40) to those who did (n = 62) over 1.-61 me. {mean 27) 
160A ABSTRACTS- Poster JACC Febnmry 1998 
Results: 
Lived Died No 8hock Shock 
Induced at RV Apex 75% 73% 83% 71% 
Induced by $2/$2S3 48% 30% 20% 52%' 
Drive cycle (ms) 400 ;t. 67 433 :~ 83 421:1; 07 474 ± 82' 
Monomorphlc VT 88% 84% 86% a1% 
RBBB morphology 81% 70% ."J 0 % 71%" 
~lperi0r Axi~ 55% 46% (]0% 47% 
$BP in VT (mmHg) 42 ,~ 35 44 ;l: 33 ~18 ± 30 49 ± 34 
VT cycle length (m,) 208 ~4S 254 ~: 47 254±40 251 ~: 4S 
~lpont, lermlnt~tlon S% 11% 10"~ 13% 
(' denotes p ~ 0,0~t) 
Conclusions: In thle high.risk population EP~i variables do not predict 
cardiac death; IlOWOVer, o~se of induolblllty (longer drive cycle length and 
1-2 oxtrastlmull) of VT and a RBBD morphology of the Induced VT was 
associated with leD shook(a) on follow.up, 
[ 1073-1751 Long-term Survival In the Antlarrhythmlce 
Ver~ua Implantable DMIbrll latom (AVID) Reglatry 
J,L, Anderson, The AVID Investigators, Unlwrslty of W~shing~on, S~lftle, 
WA, USA 
Background: AVID was e randomized trial comparing treatment with im, 
ptant~ble defibrillators vs antlarrhylhmlo drags tn ple with life-threatening 
ventrlcuhe arrhythmlas (VA), AVID also maintained a Reglefry on all pts wits 
any #gstalned VA or unexplained syncope (arrhythmla typos A-G) amenable 
to a treatment choloe aa well aa those VA (typos A-C) also eligible for the trial, 
The AVID Registry thus Included both randomized pie and those excluded 
from the main trial for any reason, 
Mefhod~: Of 6063 pts were screened. 4623 were registered, end 1016 
wore randomized, To compare mortality risk among VA types, follow-up was 
obtained on 2953 Regletry pts using the National Death Index determination 
of vital statue as of December, lg95, 
R~uff~: Mortality rates by VA type, nf n menn fnllnw-up of 11 7 ~ 80 (SD) 
moo, were: 
Ar~'hythmIR "hjpe N Do(ribs 1 
(A): VF et~tdl~c ,,lrmst 948 ~ 132 (t4%) 
(0): Syncop~l VT 399 ~ 65 (10%) 
(C): Symptomatic VT (EF : 0,40) 586 ~ 76 (13%) 
tO): Symptom~t¢ VT (EFT 040) t 58 e (6%) 
rE): Asymptomatic VT 3;'3 50 (13%) 
(F): VT-VF (Irnnsiont/corroctablo) 216 29 (13%) 
(G): Uno~(plnined syncope & inducible VT 273 25 (9'%) 
Global og,rank p= 0.0167; 1 crude do~th r~tos. Zrar.domtzod ~nd registry pts: VT, VF = 
vontrtc~,ll~r t chyc~rdio, f brillation: EF = ejection hnction 
Conclusion: Mortality in pts with serious VAs is high. "Lower risk" VAs 
(asymptomatlc VT and VTNF with correctable cause) have a similar mortality 
as "higher risk", AVID eligible VAs. Only those with VT and preserved EF 
(group D) showed a better prognosis. 
I 1 073-1 761 Dofetlllde: A New Class III Antlarrhythml¢ Drug 
Which Is Safe In Patients With Congestive Heart 
Failure 
C. To~p-Pedersen, The Danish Investigations of Arrhythmia nd Mortality 
ON Dofetilide (DIAMOND) study group. Dept. of Cardiology. Gentoffe 
University Hospital. Copenhagen. Denmark 
Backgreund: Arrhythmias are common in patients with congestive heart 
failure (CHF) but available antiarrhythmic drugs have severe side effects or 
the safety is questionable. 
Methods: In 34 Danish coronary care units 5548 consecutive patients 
admitted with newly developed or worsening congestive heart failure were 
screened and left ventricular function was assessed using echocardiography, 
Left ventricular dysfunction (wall motion index _< 1.2 corresponding to a left 
vontricular ejection fraction _<0.35) was found in 2552 patients, and of these 
1518 gave informed consent and were randomised to receive dofetilide or 
placebo. Dofetilide was dosed between 0.25 mg and 1 mg daily depending on 
renal function and presence of atrial fibrillation. All patients were monitored 
with continuous telemet~ for the initial R days of the study. The primary end 
poitlt was ad cause mortality and minimum follow up was 1 year, 
Results: In the dofetilide group 311/762, 41% died and in the placebo 
group 317.,756. 42%. The overall risk reduction on dofetilide was 0.95 (95% 
contidence limits 0.81-1.11, p = 0.56). At one year there was a 1.7% lower 
mortality on dofetilide with 95% confidence limits of ± 4% 
Conclusions: These results demonstrate that treatment with dofetitide in 
CHF patients with I,~tt ventricular dysfunction was neutral with respect to all 
cause mortnti~, ,~nmp~red toplacebo. 
I 1073-1771 Treatment of Dyarhythmlae After CABG-Surgery 
With the Amlodarone-derlvetive E 047/1 
H. Gombotz, M, VIcenzi. E, Mahla, H, Metzler, Dept. of Anesthesiology and 
Intensive Care, University of Graz, Austria 
Background: Dysryhthmlas may Jeopardize patients immediately after CABG- 
surgery. The therapeutic regimen, however, Is under discussion end the 
seamh for an Ideal drug Iscontlnuing, Experimentally, the amiodamne.derlva. 
five E047/1, wl~h e half life of 6 hrs, reduced ventdcular ectoplea, markedly 
suppressed VF end did not influence conduction end hemodynemtce, Thte 
phnso II study of E04711 investigated tolemblllty end efflceW In the trsetment 
el postoperative dyerhythmiea, 
Patients and Mefhod~: After approval by the Ethics Commltt~ end written 
consent, 20 CAC3G.petlonte (moan ¢ SO 06 ~ 5 ym, 78 :E 11 ks) with 
postoparetive etr~el fibrillation and/or significant ventdcular ectop!es (PVC's =, 
5/mln, couplets, triplets, VT), EF > 40%, plasma levels of K* > 3,5 and Ms++ 
~, 0,8 mmol wore included In e prospective study. E047/1 wee administered 
by bolus (1 rsg/kg for 10 rain) end contlnuoue infusion (t mgrkg/hr for 2 hrs), 
In addition to etendercl monitoring, dysrhythmlee were recorded continuously 
(CER Patient Monitor, Hewlett Packerd)~ Using thermodilution technique, 
homodynamloa nd derived I~rsmetere were detem,~ioed before, 10, 20, 
30, 60 end 120 mio, effor drag initiation, ECG tracings were analyzed by a 
blinded investigator. Frtedman's ANOVA was used for statistics, P < 001 
was accepted ¢~e ignitic~llt, 
Results: In 17 pationte with ventrioular ecfopies, E 047/1 induced a 55% 
reduction el dysrhy~hmias after 15 rain increasing to e 93% reduction after 
60 rain. Heart rata (93 ~_ 11 bpm), PQ. (t 58 ± 22 me), QT-intervals (379 ± 33 
ms) and hemodYnemtoa did not change troro baseline, Atdal lionllstioo was 
converted to SA rhythm in 2 el 7 patients. No adverse reactions occurred+ 
Conclusions: E 047/1 appears to be n safe, effective and rapid acting drag 
for postoperative ventrioular dysrhythmiaa, 
11073:1781. IS Induction Of Very Rapid Sustained VT 
Signif icant In PaUents With Syncope? 
S. Mittal, K.M. Stein, SM. MarkowiIz, D.J Slotwiner, MJ. Wong, 
B.B. Lerman. The New York HospttaI.Cornell University Medical Center, 
New York. NY, USA 
ICD implantation has become accepted therapy (Rx) for pts with syncope 
and inducible ventdcular arrhythmias who do not have clinically documented 
VT. It is not known, however, whether the cycle length (CL) of induced VT at 
EPS is an important prognostic determinant in this population. Specdicatly, 
the prognostic significance of very rapid monomocphic VT (<250 ms), which 
can be considered a non-specific response to the stimulation pmtecol, is 
unknown in pts without documented VT. We evaluated 25 consecutive pts 
(21 M, ago 67 ± 11 years, EF 29 ± 11%) who received an ICD for syncope 
and inducible sustained VT. Pts were followed until their first arrhythmic event 
requinng ICD Rx. Flu was available in 21 pts; of the 4 pts lost to flu, 3 died 
of unknown c~use before their first ICD interrogation, g pls had VT or VF 
requiring appropriate ICD Rx. The 30, 90, and 360 day probability of requmng 
ICD Rx was 22%, 42% and 54%. Pts with induced VT <250 ms (n = 10) and 
~250 ms (n = 11 ) had a similar likelihood of events. 
90 t 
- - [  p;= 
OI . . . . . . . . .  
30 go ~ 120 leo 180-.~0 
]L~OU.OW.1LtP ~IOPtZliS) 
Conclusions: Pts with ICDs for syncope have a significant incidence of 
arrhythmic events requiring ICD Rx. Pts are likely to have events irmspectwe 
of the cycle length of induced VT. Very rapid monomorphic VT induced 
during EPS should not be considered a non-specific finding; aggressive Rx 
is warra~ ,ted in these p~s with syncope. 
